Patent intelligence · US
US 12083184
Hydrogel prodrug for treatment
Hydrogel prodrug for treatment
Patent details — US 12083184
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 10, 2024
- Expiration
- Sep 5, 2044
- Applicant
- Viking Scientific, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/195, A61K31/197, A61K31/198
Quick answer
US 12083184 (Hydrogel prodrug for treatment) is held by Viking Scientific, Inc.. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Viking Scientific, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/195, A61K31/197, A61K31/198, A61K31/245, A61K31/522
More from Viking Scientific, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421282
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 12318426
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 12102646
Compositions for the treatment of fibrosis and inflammation
granted -
US 11951114
Use of thyroid beta-agonists
granted -
US 11752217
Hydrogel prodrug for treatment
granted -
US 11744873
Compositions and methods for the treatment of metabolic and liver disorders
granted -
US 11707472
Compositions for the treatment of fibrosis
granted
Frequently asked questions
What is US patent 12083184?
US 12083184 (Hydrogel prodrug for treatment) is held by Viking Scientific, Inc.. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12083184?
Viking Scientific, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 12083184 expire?
Our index shows an expiration date of Sep 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.